Global Next Generation Cancer Diagnostics Industry (2020 to 2027) - Market Trajectory & Analytics - ResearchAndMarkets.com

The "Next Generation Cancer Diagnostics - Global Market Trajectory & Analytics" report has been added to ResearchAndMarkets.com's offering.

Amid the COVID-19 crisis, the global market for Next Generation Cancer Diagnostics estimated at US$7.1 Billion in the year 2020, is projected to reach a revised size of US$13.3 Billion by 2027, growing at a CAGR of 9.4% over the analysis period 2020-2027.

qPCR & Multiplexing, one of the segments analyzed in the report, is projected to record a 9.8% CAGR and reach US$5.4 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Next Generation Sequencing segment is readjusted to a revised 9% CAGR for the next 7-year period.

The U.S. Market is Estimated at $2.1 Billion, While China is Forecast to Grow at 8.8% CAGR

The Next Generation Cancer Diagnostics market in the U.S. is estimated at US$2.1 Billion in the year 2020. China, the world's second largest economy, is forecast to reach a projected market size of US$2.3 Billion by the year 2027 trailing a CAGR of 8.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 8.7% and 7.7% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 7.6% CAGR.

LOAC & RT-PCR Segment to Record 10.3% CAGR

In the global LOAC & RT-PCR segment, USA, Canada, Japan, China and Europe will drive the 10.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$821.4 Million in the year 2020 will reach a projected size of US$1.6 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$1.5 Billion by the year 2027.

Select Competitors (Total 33 Featured):

• Abbott
• Agilent Technologies
• Almac Group
• Cepheid
• F. Hoffmann-La Roche Ltd
• GE Healthcare
• Genomic Health
• Hologic
• Illumina
• Janssen Global Services
• Koninklijke Philips N.V
• Myriad Genetics
• Novartis AG
• Opko Health
• PerkinElmer
• Qiagen
• Sysmex Corporation
• Thermo Fisher Scientific

Key Topics Covered:

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

• Influencer Market Insights
• World Market Trajectories
• Impact of Covid-19 and a Looming Global Recession

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

4. GLOBAL MARKET PERSPECTIVE

III. MARKET ANALYSIS

IV. COMPETITION

• Total Companies Profiled: 33

For more information about this report visit https://www.researchandmarkets.com/r/zb6yag

View source version on businesswire.com: https://www.businesswire.com/news/home/20210408005368/en/